Mumbai, July 10 -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT(R) protein platform, for oncology and autoimmune diseases.

Published by HT Digital Content Services with permission from Capital Market....